BioSpace News Archive

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 40th Annual Cowen Health Care Conference on Tuesday, March 3rd at 12:00pm EST.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has appointed former Pfizer chief financial officer (CFO), Alan G. Levin, to its board of directors (BOD).

eSolutions, a leading healthcare technology company, has released an enhancement to its Durable Medical Equipment Eligibility platform called DME Same or Similar.

Allecra Therapeutics today announced that its investigational product EXBLIFEP (cefepime-enmetazobactam) met the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) pre-specified primary endpoint in the Phase 3 ALLIUM clinical trial in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). In addition, EXBLIFEP demonstrated superiority over piperacillin-tazobactam.

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter and full year 2019 financial results and recent operating progress before the market opens on Tuesday, March 3, 2020.

Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, will be hosting a webinar at 1:30 pm ET / 10:30am PT on Thursday, February 27, 2020, to provide an update on its XBAR™ technology for non-mobile applications and Resonant’s role in the upcoming 5G revolution

Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided an operational update.

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Cowen 40th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 10.00 am ET.

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector™ targeting the suprachoroidal space were given this month at the 17th Annual Angiogenesis Meeting and 43rd Annual Macula Society Meeting.